NASDAQ$ANIK
Anika Therapeutics Inc · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Reported financial results with revenue increase and acquisitions completed.
Anika Therapeutics reported a 10% year-over-year increase in total revenue for the fourth quarter of 2019. The company completed acquisitions of Parcus Medical and Arthrosurface and expects total revenue growth in the 40% to 44% range for the full year 2020.
- Total revenue increased 10% year-over-year for Q4 2019.
- Acquisitions of Parcus Medical and Arthrosurface were completed.
- Company expects total revenue growth in the 40% to 44% range for full year 2020.
- Non-GAAP adjusted EBITDA is expected to be in the high-$40 million to high-$50 million range.
Headline financials
Revenue & EPS history
Anika · Revenue · Quarterly
$29.8M
Forward guidance
Anika Therapeutics expects total revenue to be in the range of $160 million to $165 million for the full year of 2020. Total operating expenses are anticipated to be in the $150 million to $155 million range. Non-GAAP adjusted EBITDA is expected to be in the high-$40 million to high-$50 million range, which is based on anticipated U.S. GAAP net income in the $5 million to $12 million range. Non-GAAP adjusted net income is expected to be in the mid-$20 million to low-$30 million range.
Tailwinds
- Total revenue to be in the range of $160 million to $165 million for the full year of 2020.
- Licensing, milestone and contract revenue is expected to be flat for the year.
- Product gross margin is expected to return to the 70% range in 2021.
- Non-GAAP adjusted EBITDA is expected to be in the high-$40 million to high-$50 million range.
- Capital expenditures are expected to be between $5 million and $7 million for 2020.
Headwinds
- Total operating expenses are anticipated to be in the $150 million to $155 million range.
- Product gross margin is expected to be in the low-60% range due to acquisition related one-time fair-value accounting adjustments.
- Non-GAAP adjusted EBITDA and non-GAAP adjusted net income exclude non-cash charges related to acquisition purchase accounting and non-recurring integration costs currently estimated to be approximately $27 million.
- The final fair value determination of acquisition-related purchase accounting may differ materially from the preliminary estimates.
- This guidance incorporates the Company’s best estimates for the acquired Arthrosurface and Parcus Medical businesses, which closed in late January and early February of 2020.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2019
+0.1%
Avg return
Earnings day
-3.0%
Avg return
5 days after
-2.8%
Avg return
30 days after
51%
33 / 65 earnings
Positive
+32.1%
Q3 2019
Best reaction
-33.0%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -18.8% | -4.7% | -4.8% | |
| Q4 2025 | +16.8% | +31.6% | +30.5% | |
| Q3 2025 | +0.8% | -0.5% | +2.1% | |
| Q1 2025 | -20.7% | -23.2% | -23.0% | |
| Q4 2024 | -11.1% | -7.3% | -20.3% | |
| Q3 2024 | -33.0% | -34.0% | -28.2% | |
| Q2 2024 | -1.0% | -3.6% | -5.4% | |
| Q1 2024 | -10.9% | -9.9% | -9.1% | |
| Q4 2023 | -4.8% | -2.0% | -3.1% | |
| Q3 2023 | +7.4% | +6.7% | +15.2% | |
| Q2 2023 | -4.9% | -12.7% | -18.0% | |
| Q1 2023 | -2.8% | -3.2% | +3.2% | |
| Q4 2022 | -18.0% | -17.4% | -10.4% | |
| Q3 2022 | +0.3% | +5.3% | +6.3% | |
| Q2 2022 | -4.9% | -2.7% | -6.0% | |
| Q1 2022 | -4.9% | -3.8% | +1.1% | |
| Q4 2021 | -15.9% | -18.0% | -20.1% | |
| Q3 2021 | +3.1% | -8.2% | -12.8% | |
| Q2 2021 | +1.0% | +0.8% | +1.3% | |
| Q1 2021 | +1.3% | +2.8% | +10.9% | |
| Q4 2020 | -10.5% | -12.1% | +3.9% | |
| Q3 2020 | -3.3% | +0.2% | +7.6% | |
| Q2 2020 | +0.3% | -8.7% | +2.9% | |
| Q1 2020 | -9.9% | -12.2% | +9.1% | |
| Q4 2019 | +0.4% | +0.1% | -39.5% | |
| Q3 2019 | +32.1% | +21.5% | +3.7% | |
| Q2 2019 | +29.1% | +31.0% | +37.2% | |
| Q1 2019 | +19.6% | +21.5% | +15.9% | |
| Q4 2018 | -15.3% | -18.8% | -26.5% | |
| Q3 2018 | -11.0% | -13.6% | -13.9% | |
| Q2 2018 | +18.6% | +15.0% | +20.8% | |
| Q1 2018 | -22.9% | -15.7% | -8.6% | |
| Q4 2017 | -4.0% | -11.3% | -17.4% | |
| Q3 2017 | -8.0% | -9.2% | -8.0% | |
| Q2 2017 | +7.1% | +6.0% | +9.3% | |
| Q1 2017 | -5.5% | -1.8% | +0.4% | |
| Q4 2016 | -5.0% | -5.1% | -16.4% | |
| Q3 2016 | +2.0% | +2.7% | +8.0% | |
| Q2 2016 | -5.0% | -2.3% | -6.7% | |
| Q1 2016 | +0.5% | — | — | |
| Q4 2015 | +11.2% | — | — | |
| Q3 2015 | +12.5% | — | — | |
| Q2 2015 | +3.2% | — | — | |
| Q1 2015 | -7.5% | — | — | |
| Q4 2014 | -10.7% | — | — | |
| Q3 2014 | +1.0% | — | — | |
| Q2 2014 | +4.1% | — | — | |
| Q1 2014 | +7.7% | — | — | |
| Q4 2013 | +26.9% | — | — | |
| Q3 2013 | +6.5% | — | — | |
| Q2 2013 | +21.9% | — | — | |
| Q1 2013 | -1.8% | — | — | |
| Q4 2012 | +16.6% | — | — | |
| Q3 2012 | -7.7% | — | — | |
| Q2 2012 | +24.4% | — | — | |
| Q1 2011 | +0.6% | — | — | |
| Q1 2012 | +2.8% | — | — | |
| Q4 2009 | +1.5% | — | — | |
| Q4 2011 | +1.5% | — | — | |
| Q3 2011 | +7.0% | — | — | |
| Q3 2010 | +7.0% | — | — | |
| Q2 2010 | -3.4% | — | — | |
| Q4 2010 | -3.4% | — | — | |
| Q2 2011 | -3.4% | — | — | |
| Q1 2010 | -1.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro